Urinary tract infections (UTIs) are a common burden ... Herein we discuss the aetiology, pathogenesis and management of UTI and its local and more remote complications.

Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.

Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo UPLIZNA Shown t ...

The most common adverse reactions reported during the trial with inebilizumab were urinary tract infections and lymphopenia ... approach to help address the pathophysiology of IgG4-RD ...

Complicated urinary tract infections. StatPearls ... Sepsis and septic shock – basics of diagnosis, pathophysiology and clinical decision making. Med Clin North Am. 2020;104(4):573-585.

An uncomplicated urinary tract infection (UTI) can sometimes go away on its own without treatment. This is especially true for a UTI without symptoms, known as asymptomatic bacteriuria. Some mild ...

Uplizna is the first approved treatment for immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory condition ...

US FDA approves Amgen’s Uplizna to treat IgG4-related disease: Thousand Oaks, California Saturday, April 5, 2025, 11:00 Hrs [IST] Amgen announced that the US Food and Drug Admin ...